Cancer Stem Cells in Soft-Tissue Sarcomas

被引:16
作者
Martinez-Delgado, Paula [1 ]
Lacerenza, Serena [1 ]
Obrador-Hevia, Antonia [2 ,3 ]
Lopez-Alvarez, Maria [1 ]
Mondaza-Hernandez, Jose L. [1 ]
Blanco-Alcaina, Elena [1 ]
Sanchez-Bustos, Paloma [1 ]
Hindi, Nadia [1 ,4 ]
Moura, David S. [1 ]
Martin-Broto, Javier [1 ,4 ]
机构
[1] Univ Seville, Inst Biomed Seville IBIS, CSIC, HUVR, Seville 41013, Spain
[2] Son Espases Univ Hosp, Hlth Res Inst Balearic Isl IdISBa, Palma De Mallorca 07120, Spain
[3] Son Espases Univ Hosp, Mol Diag Unit, Palma De Mallorca 07120, Spain
[4] Univ Hosp Virgen del Rocio, Med Oncol Dept, Seville 41013, Spain
关键词
cancer stem cells; tumor-initiating cells; soft-tissue sarcoma; chemotherapy resistance; stemness; tumor heterogeneity; genetic and epigenetic plasticity; HISTONE DEACETYLASE INHIBITORS; INDUCED KILLER-CELLS; SYNOVIAL SARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; SELF-RENEWAL; PHASE-II; CD133(+) SUBPOPULATION; LIPOSOMAL DOXORUBICIN; MULTIDRUG-RESISTANCE; TREATED PATIENTS;
D O I
10.3390/cells9061449
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic profiles and clinical features. Systemic chemotherapy is the backbone treatment for advanced STS; however, STS frequently acquire resistance to standard therapies, which highlights the need to improve treatments and identify novel therapeutic targets. Increases in the knowledge of the molecular pathways that drive sarcomas have brought to light different molecular alterations that cause tumor initiation and progression. These findings have triggered a breakthrough of targeted therapies that are being assessed in clinical trials. Cancer stem cells (CSCs) exhibit mesenchymal stem cell (MSC) features and represent a subpopulation of tumor cells that play an important role in tumor progression, chemotherapy resistance, recurrence and metastasis. In fact, CSCs phenotypes have been identified in sarcomas, allied to drug resistance and tumorigenesis. Herein, we will review the published evidence of CSCs in STS, discussing the molecular characteristic of CSCs, the commonly used isolation techniques and the new possibilities of targeting CSCs as a way to improve STS treatment and consequently patient outcome.
引用
收藏
页码:1 / 22
页数:21
相关论文
共 136 条
[51]   EMT- and MET-related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities [J].
Kahlert, Ulf D. ;
Joseph, Justin V. ;
Kruyt, Frank A. E. .
MOLECULAR ONCOLOGY, 2017, 11 (07) :860-877
[52]   Aberrant epigenetic regulation in clear cell sarcoma of the kidney featuring distinct DNA hypermethylation and EZH2 overexpression [J].
Karlsson, Jenny ;
Valind, Anders ;
Jansson, Caroline ;
O'Sullivan, Maureen J. ;
Mengelbier, Linda Holmquist ;
Gisselsson, David .
ONCOTARGET, 2016, 7 (10) :11127-11136
[53]   What makes cancer stem cell markers different? [J].
Karsten, Uwe ;
Goletz, Steffen .
SPRINGERPLUS, 2013, 2 :1-8
[54]   Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma (vol 11, e0158888, 2016) [J].
Kawano, Satoshi ;
Grassian, Alexandra R. ;
Tsuda, Masumi ;
Knutson, Sarah K. ;
Warholic, Natalie M. ;
Kuznetsov, Galina ;
Xu, Shanqin ;
Xiao, Yonghong ;
Pollock, Roy M. ;
Smith, Jesse J. ;
Kuntz, Kevin W. ;
Ribich, Scott ;
Minoshima, Yukinori ;
Matsui, Junji ;
Copeland, Robert A. ;
Tanaka, Shinya ;
Keilhack, Heike .
PLOS ONE, 2017, 12 (01)
[55]   Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours [J].
Kerklaan, B. Milojkovic ;
Lolkema, M. P. J. ;
Devriese, L. A. ;
Voest, E. E. ;
Nol-Boekel, A. ;
Mergui-Roelvink, M. ;
Langenberg, M. ;
Mykulowycz, K. ;
Stoebenau, J. ;
Lane, S. ;
Legenne, P. ;
Wissel, P. ;
Smith, D. A. ;
Giantonio, B. J. ;
Schellens, J. H. M. ;
Witteveen, P. O. .
BRITISH JOURNAL OF CANCER, 2015, 113 (05) :706-715
[56]   Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells [J].
Kimura, T. ;
Wang, L. ;
Tabu, K. ;
Tsuda, M. ;
Tanino, M. ;
Maekawa, A. ;
Nishihara, H. ;
Hiraga, H. ;
Taga, T. ;
Oda, Y. ;
Tanaka, S. .
ONCOGENE, 2016, 35 (30) :3932-3943
[57]   A CELL INITIATING HUMAN ACUTE MYELOID-LEUKEMIA AFTER TRANSPLANTATION INTO SCID MICE [J].
LAPIDOT, T ;
SIRARD, C ;
VORMOOR, J ;
MURDOCH, B ;
HOANG, T ;
CACERESCORTES, J ;
MINDEN, M ;
PATERSON, B ;
CALIGIURI, MA ;
DICK, JE .
NATURE, 1994, 367 (6464) :645-648
[58]   Interaction of tumor-associated macrophages and cancer chemotherapy [J].
Larionova, Irina ;
Cherdyntseva, Nadezhda ;
Liu, Tengfei ;
Patysheva, Marina ;
Rakina, Militsa ;
Kzhyshkowska, Julia .
ONCOIMMUNOLOGY, 2019, 8 (07)
[59]  
Leslie M, 2020, CANCER DISCOV, V10, P333, DOI 10.1158/2159-8290.CD-NB2020-006
[60]   The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics [J].
Liu, Aiguo ;
Feng, Baohua ;
Gu, Wenguang ;
Cheng, Xiangyang ;
Tong, Tiejun ;
Zhang, Hongzhi ;
Hu, Yongzhen .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 42 (04) :1399-1407